Skip to main content

RA/Inflammatory arthritis

Noninflammatory Pain Persists in RA Despite Treatment

Jun 02, 2020

Almost one-third of patients with new-onset rheumatoid arthritis (RA) reported persistent unacceptable pain after 21 months of combination therapy, according to a study by Swedish researchers.A total of 29% of patients continued to have unacceptable pain.

Read Article

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

May 29, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
BTK inhib (fenbrutinib-FEN) effective in #RA. In a 12 wk RCT, 480 MTX-IR pts Rx either PBO, adalimumab or FEN (50 mg or 150 mg/d). ACR50 resp was PBO 15%; ADA 36%; FEN 50mg 18%, 150 qd 28%, 200 mg bid 35%. FEM NO effx on myeloid & B cell biomarkers.

Dr. John Cush RheumNow ( View Tweet)

May 28, 2020

TNR Grand Rounds - Cytokine Storm Syndromes

May 27, 2020

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The

Read Article

Boston and Wuhan Report Rheum COVID Patients at Risk for Respiratory Failure

May 27, 2020

Two current reports from Boston and Wuhan describe cohorts of COVID-19 (+) rheumatic disease patients who generally do well but appear to have a higher risk of pulmonary involvement.

Read Article

Hydroxychloroquine Improves Survival in Lupus

May 26, 2020

Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients. Yet, a recent report reaffirms what rheumatologists have known for years - that HCQ use is associated with better outcomes in systemic lupus erythematosus, including

Read Article

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

May 25, 2020

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

Read Article
14 pts refractory AOSD pts (Yamaguchi+) showed a good response to usual doses of tofacitinib. 7/14 complete remission, 6/14 partial remission & 1 relapse w/ pred reduction. May work by reducing reducing IL-6, IL-10, IFN-γ, IFN-α, GM-CSF, neutrophils.

Dr. John Cush RheumNow ( View Tweet)

May 23, 2020
Genetic study of 57 systemic JIA children finds presence of MEFV variant p.M694V/I was a risk factor for sJIA (OR: 7.13) https://t.co/TL6WisMQo8 Other studies have shown ~31% of Still's patients at lease 1 genetic variant for periodic fever syndromes.

Dr. John Cush RheumNow ( View Tweet)

May 22, 2020
Metformin reduces RA risk in Women - Population study of 2.3 million, found 113749 starting metformin (1998-2014); 558 developed new RA. Adherence (PDC 40–59%) predicted lower adjusted hazard ratio = 0.62, moreso in women on 2550+ qd https://t.co/z6AWWlBpa2

Dr. John Cush RheumNow ( View Tweet)

May 22, 2020
Review of Rheumatic Sxs with Immune checkpoint inhibitors - Common are inflammatory arthritis, PMR & myositis. Non-MSK Sxs include sicca, vasculitides and sarcoidosis. SLE and scleroderma are extremely rare. Majority can be Rx w/ steroids.

Dr. John Cush RheumNow ( View Tweet)

May 21, 2020

No Certain Link between Biologics and Melanoma Risk

May 21, 2020

A review of available data fails to show an increased risk of melanoma in IMID (inflammatory bowel disease, rheumatoid arthritis, and psoriasis) patients treated with systemic biologic therapies.  



There have been sporadic uncontrolled observational reports suggesting a link between

Read Article
A patient service Video - How to Manage your Arthritis Medications (in the time of COVID) - View the video here: https://t.co/hWW0h8wCZn or listen to the podcast on iTunes or here>> https://t.co/8wV4V2pYY5
Dr. John Cush RheumNow ( View Tweet)
May 21, 2020
JAK inhibr safety review - Meta-analysis shows a significant 57% increase in risk of H. zoster with JAKi (RR 1.57; 1.04-2.37). Data from 82 studies, 66,159 pts w/ RA, IBD, Pso, PsA, AS. Rates of SIE=2.81/100PY and HZ=2.67/100 PY.

Dr. John Cush RheumNow ( View Tweet)

May 21, 2020
RA is associated with increased risk of heart failure (HF). Vanderbilt Univ EHR study compared 9889 RA pts vs 9889 matched non-autoimmune pts - RA had 21% greater risk of HF.

Dr. John Cush RheumNow ( View Tweet)

May 20, 2020

TNR - COVID-Rheumatology Registry & COVID in OZ

May 19, 2020

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID in

Read Article
Secukinumab shown to work in 9/15 (67%) of refractory Behçet’s patients (mucosal and articular dz) by 3 mos - Retrospective study looked a complete or partial responders. #s increased to 86.7% at 6 months.

Dr. John Cush RheumNow ( View Tweet)

May 18, 2020

High Dose Anakinra Effective in COVID-19

May 18, 2020

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared

Read Article

The Nine Lives of Hydroxychloroquine (Updated)

May 18, 2020

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article

RheumNow Podcast - COVID Kids and Men (5.15.20)

May 15, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

CDC on Pediatric Multi-System Inflammatory Syndrome

May 14, 2020

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

Read Article
Metanalysis shows Type 2 DM associated with >2-fold increased risk (aHR 2.25) of severe liver disease (NAFLD); a more modest risk w/ obesity (HR 1.20); other risk variables - low HDL, high triglycerides & hypertension were independently associated https://t.c

Dr. John Cush RheumNow ( View Tweet)

May 13, 2020
Subanalyses of Mobility and Monarch studies show that #RA patients with highest tertiles of IL-6 (and CRP) had more disease activity, more Xray damage and better responses (less Xray change) to Sarilumab (vs Adalimumab or MTX). https://t.co/5mTePETFAQ

Dr. John Cush RheumNow ( View Tweet)

May 12, 2020
The RheumNow Podcast is up - The Beat Goes On.... anakinra, nr-AxSpA, Smoking & GPA, PSS guidelines, IFNa, COVID and IL-6, HCQ,QTc, and Thromboses https://t.co/BsaALcHclv

Dr. John Cush RheumNow ( View Tweet)

May 10, 2020

RheumNow Podcast – The Beat Goes On (5.8.20)

May 07, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
×